全文获取类型
收费全文 | 1024817篇 |
免费 | 73361篇 |
国内免费 | 1733篇 |
专业分类
耳鼻咽喉 | 14051篇 |
儿科学 | 26835篇 |
妇产科学 | 24949篇 |
基础医学 | 144474篇 |
口腔科学 | 29928篇 |
临床医学 | 90562篇 |
内科学 | 201845篇 |
皮肤病学 | 20514篇 |
神经病学 | 81695篇 |
特种医学 | 40620篇 |
外国民族医学 | 82篇 |
外科学 | 167278篇 |
综合类 | 19080篇 |
现状与发展 | 1篇 |
一般理论 | 365篇 |
预防医学 | 69651篇 |
眼科学 | 23273篇 |
药学 | 78499篇 |
3篇 | |
中国医学 | 2239篇 |
肿瘤学 | 63967篇 |
出版年
2021年 | 7476篇 |
2019年 | 7860篇 |
2018年 | 11333篇 |
2017年 | 8746篇 |
2016年 | 9604篇 |
2015年 | 10965篇 |
2014年 | 15150篇 |
2013年 | 21896篇 |
2012年 | 31063篇 |
2011年 | 32420篇 |
2010年 | 19084篇 |
2009年 | 18118篇 |
2008年 | 31167篇 |
2007年 | 32630篇 |
2006年 | 33225篇 |
2005年 | 31804篇 |
2004年 | 30865篇 |
2003年 | 29246篇 |
2002年 | 28481篇 |
2001年 | 55547篇 |
2000年 | 57100篇 |
1999年 | 47808篇 |
1998年 | 11904篇 |
1997年 | 10334篇 |
1996年 | 10297篇 |
1995年 | 9569篇 |
1994年 | 8833篇 |
1993年 | 8154篇 |
1992年 | 35926篇 |
1991年 | 34319篇 |
1990年 | 33076篇 |
1989年 | 32180篇 |
1988年 | 29286篇 |
1987年 | 28532篇 |
1986年 | 26551篇 |
1985年 | 25439篇 |
1984年 | 18151篇 |
1983年 | 15402篇 |
1982年 | 8129篇 |
1979年 | 15899篇 |
1978年 | 10738篇 |
1977年 | 9165篇 |
1976年 | 7957篇 |
1975年 | 8711篇 |
1974年 | 10540篇 |
1973年 | 9934篇 |
1972年 | 9415篇 |
1971年 | 8898篇 |
1970年 | 8463篇 |
1969年 | 7964篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Hassen Lena M. Albarrak Rana A. Albahlal Reem A. Alsaqabi Dimah K. Hassen Ikhlass M. Daghestani Maha H. Alqurtas Eman M. Alkhalaf Abdulaziz T. Bedaiwi Mohammed K. Omair Mohammed A. Almaghlouth Ibrahim A. 《Quality of life research》2022,31(11):3229-3239
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional... 相似文献
2.
3.
4.
5.
6.
Timothy J. Cordingley Mark A.G. Wilson Kathryn M. Weston 《Health & social care in the community》2022,30(1):353-359
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children. 相似文献
7.
Kuo-yi Jade Chang MHealthEc MHM BSc Lisa Lorraine Dillon MSpecEd BPsych Lil Deverell COMS PhD MEd GradDipO&M BEd Mei Ying Boon PhD BOptom FAAO Lisa Keay PhD MPH BOptom 《Clinical & experimental optometry》2020,103(4):434-448
Despite orientation and mobility (O&M) being a significant factor determining quality of life of people with low vision or blindness, there are no gold standard measures or agreement on how to measure O&M performance. In the first part of this systematic review, an inventory of O&M outcome measures used by recent studies to assess the performance of orientation and/or mobility of adults with vision impairment (low vision and blindness) is presented. A wide variety of O&M outcome measures have been implemented in different fields of study, such as epidemiologic research and interventional studies evaluating training, assistive technology, vision rehabilitation and vision restoration. The most frequent aspect of outcome measures is efficiency such as time, distance, speed and percentage of preferred walking speed, followed by obstacle contacts and avoidance, and dis/orientation and veering. Other less commonly used aspects are target identification, safety and social interaction and self-reported outcome measures. Some studies employ sophisticated equipment to capture and analyse O&M performance in a laboratory setting, while others carry out their assessment in real-world indoor or outdoor environments. In the second part of this review, the appropriateness of implementing the identified outcome measures to assess O&M performance in clinical and functional O&M practice is evaluated. Nearly a half of these outcome measures meet all four criteria of face validity (either clinical or functional), responsiveness, reliability and feasibility and have the potential to be implemented in clinical or functional O&M practice. The findings of this review confirm the complicated and dynamic nature of O&M. Multiple measures are required in any evaluation of O&M performance to facilitate holistic assessment of O&M abilities and limitations of each individual. 相似文献
8.
Brittney H. Cotta Margaret F. Meagher Aaron Bradshaw Stephen T. Ryan Gerant Rivera-Sanfeliz 《Expert review of anticancer therapy》2019,19(4):301-308
Introduction: Percutaneous renal mass biopsy has evolved over the last decade with improvements on previous pitfalls including low tissue yield, high non-diagnostic rates, and complications. As understanding of tumor biology and natural history of renal cortical neoplasms has improved, percutaneous renal mass biopsy is poised to have an expanding role in an area characterized by individualized management and refined risk stratification.
Areas covered: This review summarizes the evolution of renal mass biopsy to its current state with respect to outcomes, indications, and clinical guidelines.
Expert opinion: With improved understanding of differential biological potential of renal cortical neoplasms combined with technical improvements in diagnostic yield and accuracy, utilization of renal mass biopsy is becoming an important adjunct to patient care in a broad range of clinical scenarios, including active surveillance, thermal ablation, and use of primary systemic therapy in localized and advanced settings. 相似文献
9.
10.